We have an OH&S Safety Practice of using only SESDs in hospital settings for insulin pens and other pen type medications, such as Ozempic.
The BD Autoshield Duo satisfies the SESD requirement, but the pen needles that are provided by the manufacturers are not SESD compliant.

I've confirmed that Ozempic pens can be used and compatible with BD Autoshield Duo Pen Needles.

How has your organization gone about educating and also recognizing a safety practice like this for medications and products like Ozempic?

Furthermore, it was discovered that due to the look-alike nature of the Ozempic pens to Insulin Pens, and using the same SESD pen needles, our frontline staff assumed that Ozempic pens with the BD Autoshield Duo would be "primed" the same way as Insulin Pens (ie. 2 units with every new pen needle). However, Ozempic does not require a "prime" with each pen needle, but rather an initial, one-time Flow Check, not dependent of the type of pen needle used.

In your organization, who's responsibility is it to ensure that these medication products and their nuances are discovered, vetted, communicated, and educated to the frontline staff?